How many of these 7 ADC handling considerations are on your radar?
As pipelines for ADCs mature, payloads become more potent, and linker technologies grow more sophisticated, the operational demands surrounding ADC manufacturing are intensifying rapidly. At the same time, development timelines are compressing, and expectations regarding safety, reproducibility, and regulatory compliance continue to rise.
What may work for monoclonal antibodies is increasingly insufficient for ADCs. Nowhere is this more apparent than in fluid handling and cold chain management, where conventional methods are being pushed to their limits.
Below are seven considerations that increasingly define how ADCs are handled today. Not in theory, but in real manufacturing environments where safety, precision, and scalability must work together.
1. Safety first when handling cytotoxic ADCs
Unlike traditional biologics, ADCs introduce cytotoxic risk directly into routine liquid handling steps. Even brief exposure during transfers, draining, or filling can pose significant hazards to operators.
The cytotoxicity has reshaped facility and process designs. Closed handling architectures are becoming the baseline. EU GMP Annex 1 reinforces this shift by explicitly promoting closed systems to reduce both contamination risks and personnel exposure.
Cold chain operations further amplify the stakes. Frozen products place mechanical stress on single‑use containers, increasing the consequences of bag breakages. Secondary packaging for single-use bioprocess containers during frozen handling adds a critical layer of protection, both for product integrity and for operator safety.
2. Light: the invisible threat to your ADC
Light exposure is unavoidable in biomanufacturing. For example, regulatory standards such as USP <790> even require defined lighting conditions for visual inspection. However, not all light exposure is harmless.
Many ADC payloads contain photosensitive functional groups that can degrade under ambient or UV light. The challenge is compounded by the fact that the antibody, linker, and payload may each respond differently, allowing degradation to begin without obvious visual cues.
Because only a limited number of single‑use bags provide intrinsic UV protection, manufacturers increasingly rely on secondary containment. Secondary packaging, like the RoSS® shell, that fully encloses single-use bags and assemblies can help reduce unnecessary exposure during transport and storage, while black‑film materials can provide additional protection when photostability risks are high.
3. The fluid path is where patient safety begins
Patient safety is engineered long before a drug reaches the clinic. In ADC manufacturing, closed system devices directly influence how accurately and consistently material is transferred and filled.
Small variations in geometry, internal volume, or processes can result in product loss, residual volume, or dose variability. All of these factors are becoming increasingly critical for patient safety. Poorly controlled fill paths also complicate validation activities and comparability across sites.
Recipe‑driven, closed filling strategies help address these risks by delivering reproducible performance and predictable holdup volumes. Establishing well‑defined fluid paths early in development creates a more reliable foundation for scale‑up and supports patient safety when handling highly potent materials.
4. Weakest link(er) in ADC cold chain
Freezing and thawing represent some of the most critical moments in an ADC’s lifecycle. Known challenges such as cryoconcentration, aggregation, and pH shifts are well documented, but for ADCs, the linker often represents the most sensitive point of failure. Many linker chemistries are temperature‑ and pH‑dependent. Uncontrolled freeze–thaw cycles can therefore undermine conjugation integrity, even when the antibody itself appears unaffected.
This has led to a shift towards controlled, recipe‑based freezing and thawing methods that help maintain the molecular structure. By actively managing cooling rates, phase transitions, and thawing profiles, manufacturers can reduce variability and better preserve critical quality attributes more effectively during storage and transport.
5. Every drop counts: Losses are no longer tolerable
The value density of modern ADCs continues to rise. Higher drug‑to‑antibody ratios (DAR), increasingly potent payloads, and advanced linker technologies have dramatically increased the financial impact of even small losses.
At the same time, the industry is expanding beyond classical ADCs into next‑generation bioconjugates, including nanoparticle‑based systems and polysaccharide‑linked vaccines. In this environment, losses due to contamination, container failure, excessive holdup volumes, or inaccurate filling are no longer acceptable.
Protecting product value now requires the same level of precision and control long associated with drug substance manufacturing.
6. ADC manufacturing rarely follows a straight line
Batch sizes fluctuate, indications evolve, scaling requirements change, and production is often transferred between internal sites and CDMOs.
Rigid infrastructures struggle under this variability. Manufacturers increasingly require solutions that allow volumes to scale without redesign, container formats to change without requalification, and processes to be transferred efficiently between sites.
Modular, flexible platforms paired with automation throughout filling, freezing, storage and transport are emerging as key enablers of process flexibility. Scalable process solutions for single-use systems, like bags and bottles, help manufacturers respond to change without compromising safety, control, or compliance.
7. Think end‑to‑end
Many ADC handling challenges cannot be solved in isolation. Operator safety, product quality, cold chain stability, and scalability are deeply interconnected.
End‑to‑end handling strategies that combine closed fluid management, protected storage, and controlled freezing and thawing help reduce interfaces and manual interventions. The result is a more robust process that is easier to control. Plus, it is easier to adapt as ADC programs evolve.
Handling ADCs with confidence, not compromise
Single Use Support helps manufacturers implement safe, closed, and scalable ADC fluid and cold chain management throughout the development and commercial manufacturing steps. From automated filling and protected storage to controlled freezing and thawing, integrated solutions are designed to navigate these 7 (and more) key ADC workflows in fluid and cold chain management. Handling increasingly potent and valuable ADCs with confidence helps reduce manufacturing risk while preserving product integrity.